10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Friday, August 14, 2009

Bal Pharma Ltd:Can be a potential winner in the pharma segment

Scripscan:Bal Pharma Ltd

Story:Bal Pharma is a leading Indian Pharmaceutical Company specializing in Prescription drugs, Generics, OTC products, Intravenous Infusion and Bulk Actives with almost 19 years of experience behind it.Successful operations in Domestic and various International markets, backed by strengths in Research and strong Infrastructure frame work have accelerated Bal pharma’s growth from oblivience to reach a turnover of USD 25 million today. Buoyed by the past, the group has put in motion a fast track growth target and has set its sight on sales in excess of USD 150million by 2012.Its branded formulations business division is focussing much on marketing Cardiac and Diabetic products by introducing 6 more new products and strengthening the sales manpower by another 25%.The performance of the division is being escalated to further heights by increasing market share in Northern India. The new Formulation Plant with the state of art designed facility for regulated market is complete in the Excise Free Zone of Uttaranchal. The trial runs are going on and commercial production is expected shortly.The company has also acquired 10 acres of land in SEZ Pharma Zone in Hassan, Karnataka to increase its bulk drug manufacturing capacity. The project is expected to complete by the year 2010.All thesedevelopments are expected to catapult the company in the big league.The company has also entered the Japanese market and thats expected to account for about 15 per cent of the company's revenues in the next two years.Bal Pharma forayed into herbal products six years ago and currently has number of products in the segment, with most of the products contract manufactured.The ayurvedic products division too is expected to contribute about Rs 10 crore to company turnover by 2010.The company has been paying dividends for last year with present year been no exception as it rewarded the shareholders with a 7.5%dividend.At 20 odd rs it worthbuying.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner